Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On January 26, 2023, Eric Ostertag, M.D., Ph.D., informed the Board of Directors
(the "Board") of Poseida Therapeutics, Inc. (the "Company") of his decision to
resign from his position as Executive Chairman of the Board, effective
February 3, 2023. Dr. Ostertag's resignation is not a result of any disagreement
with the Company on any matter relating to the Company's operations, policies or
practices. In connection with Dr. Ostertag's resignation, the Company plans to
enter into a transition and consulting agreement with Dr. Ostertag (the
"Transition Agreement"), pursuant to which Dr. Ostertag will provide consulting
services to the Company with respect to technical and scientific matters in
consideration of continued vesting of his outstanding equity awards, a
single-trigger acceleration benefit applicable to such outstanding equity awards
and payment of his monthly health insurance premiums under COBRA for up to an
eighteen month period following his resignation.
On January 31, 2023, the Company issued a press release announcing the
resignation of Dr. Ostertag, a copy of which is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press Release of Poseida Therapeutics, Inc., dated January 31, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
POSEIDA THERAPEUTICS, INC. 
